{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/nsaids-prescribing-issues/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"f6920c2a-03f6-5506-aec1-3fdde89dd2f7","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 57d6bba1-cddd-4f90-9e98-ece56a7673a3 --><h2>Changes</h2><!-- end field 57d6bba1-cddd-4f90-9e98-ece56a7673a3 -->","summary":null,"htmlStringContent":"<!-- begin item ec7cf90c-0bff-4709-a46e-2b265e4245d5 --><!-- begin field c906b236-281f-490a-881c-c6aba5671241 --><p><strong>April 2020 </strong>— minor update. New management scenario created to provide information regarding COVID-19.</p><p><strong>August 2019</strong> — minor update. Anastomotic leakage and 'Kounis syndrome' (allergic acute coronary syndrome) have been added as adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">ABPI, 2019</a>].</p><p><strong>August 2018</strong> — reviewed. A literature search was conducted in August 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic.</p><p> </p><!-- end field c906b236-281f-490a-881c-c6aba5671241 --><!-- end item ec7cf90c-0bff-4709-a46e-2b265e4245d5 -->","topic":{"id":"ceac2e33-6fd9-5bdf-a103-bdeff3e6efe7","topicId":"5e29889f-d8f4-4f4e-9bce-78c262cd5e62","topicName":"NSAIDs - prescribing issues","slug":"nsaids-prescribing-issues","lastRevised":"Last revised in April 2020","chapters":[{"id":"81e21dc7-3fa3-5a27-a799-d7e553aa1b01","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e5927ea9-133a-5f9b-a357-a61c0992b6c6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f8ed8fe1-df7d-5125-937f-2d1e3501233c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f6920c2a-03f6-5506-aec1-3fdde89dd2f7","slug":"changes","fullItemName":"Changes"},{"id":"7e3ebe71-e455-5372-ae22-416ce6a0b71a","slug":"update","fullItemName":"Update"}]},{"id":"acb8e014-609e-5dc6-9f65-30c1458821c4","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"93d7bec8-79d3-5e43-b717-afe25c73d3ca","slug":"goals","fullItemName":"Goals"},{"id":"80a6271f-7ea5-5a98-902b-a008dc09f1ee","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6782e03f-1ef7-5af4-86c0-eb675a202116","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fcacc99e-0dfb-5679-b56f-f8205eba1edc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"15a07f25-5af2-57a1-a7ac-048177f2fb99","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"39c204ac-0dfe-5334-ba6a-72f81053bd3d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9ce106c0-0dc6-5564-9353-be22c8fc1ed5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0cc396a7-37bb-55ac-a9b6-83b76805f342","slug":"definition","fullItemName":"Definition"},{"id":"d742f98e-351a-50ba-bc7a-d0ecc0e7689d","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"93f69297-618f-59f0-b4d4-f6e50bdf5467","slug":"classification","fullItemName":"Classification"}]},{"id":"6537c6fb-b310-5291-98df-d01a4e961e7e","fullItemName":"Management","slug":"management","subChapters":[{"id":"f7cf8186-98aa-5332-bbd7-7ac7f7c5748e","slug":"nsaids-prescribing-issues","fullItemName":"Scenario: NSAIDs  prescribing issues"}]},{"id":"1e3b7407-6a49-5511-bff4-c0f0e8e7b22e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"56eccf0e-4660-56df-8972-3fc937ad78b7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"80126798-6f53-5ceb-b2d7-d2c5adf206da","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0e838f63-dbcc-5df4-ba98-67f8c94448ed","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"179593fd-6f34-5834-a706-a5b7abb725a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b21e3781-fcad-52bd-b0b3-0b7f267e817d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ece91260-71c4-51d6-bc77-400de18b4802","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dedb4c68-d2e7-53bb-81ef-03a9600c383d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f8ed8fe1-df7d-5125-937f-2d1e3501233c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"aaf7fc0d-ee69-5723-9c2d-7a75dd37a975","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field b0362648-1692-4e54-8b46-fdaf5e1e782a --><h3>Previous changes</h3><!-- end field b0362648-1692-4e54-8b46-fdaf5e1e782a -->","summary":null,"htmlStringContent":"<!-- begin item 97421293-b0f4-475b-9efb-ab3a675a5b9a --><!-- begin field 2fec161c-84b8-486c-a9d8-298412b93256 --><p>​​​​​​​​​​​​​​<strong>July 2015 </strong>— minor update. The topic has been updated to reflect the European Medicines Agency (EMA) <em>Updated advice on use of high-dose ibuprofen</em>. </p><p><strong>July 2013 </strong>— minor update. Update to the text to reflect new recommendations by the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Diclofenac: new contraindications and warnings after a Europe-wide review of cardiovascular safety</em>.<em> </em>The MHRA now recommends that, like coxibs, diclofenac is contraindicated for people with ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, and congestive heart failure (New York Heart Association [NYHA] classification II–IV).</p><p><strong>January 2013 </strong>— reviewed. A literature search was conducted in December 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. There are no changes to the recommendations; however, this topic has been restructured for the purposes of clarity.</p><p><strong>November 2012 </strong>— minor update. The links to the electronic medicines website (<a data-hyperlink-id=\"e8fe04b4-44d7-4c40-a638-a93100bf7787\" href=\"http://www.medicines.org.uk/\">www.medicines.org.uk</a>) have been updated.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>May 2011 </strong>— minor update. Text updated to include more detailed advice about the use of paracetamol in pregnancy. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— technical update. The management section of this topic has been simplified to improve clarity and navigation. There have been no changes to the clinical content or meaning of the recommendations.</p><p><strong>September 2010 </strong>— minor update. Additional advice about the risk of using NSAIDs in people with hepatic impairment has been added. Issued in September 2010.</p><p><strong>June to July 2010 </strong>— updated to include more detailed advice on contraindications and monitoring of people with co-morbidities taking NSAIDs. The <em>Supporting evidence </em>section on the thrombotic risks associated with using NSAIDs has also been updated. Issued in August 2010.</p><p><strong>January 2010 </strong>— advice on safety of NSAIDs during conception, pregnancy, and breastfeeding has been updated. Issued in January 2010.</p><p><strong>December 2009 </strong>— minor update. Clarification that selective serotonin reuptake inhibitors are associated with an increased risk of bleeding, and should be avoided if a person is taking an NSAID, if possible, in line with NICE guidance <em>Depression in adults with a chronic physical health problem.</em> Issued in December 2009.</p><p><strong>August 2009 </strong>— minor update. Clarification that the National Institute for Health and Clinical Excellence (NICE) advise that proton-pump inhibitors (PPIs) should routinely be co-prescribed for anyone with osteoarthritis or rheumatoid arthritis, and anyone 45 years of age and older with chronic low back pain. Issued in August 2009.</p><p><strong>May 2009 </strong>— the <em>Supporting evidence </em>section has been updated with an additional case-control study that was highlighted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the <em>Drug safety update</em>, reminding prescribers that NSAIDs should be prescribed with caution in people with established renal impairment, or who are at risk of renal impairment. Issued in June 2009.</p><p><strong>April 2009 </strong>— minor update. Information added, highlighting the rare risk of severe hepatic adverse effects when using celecoxib and etoricoxib, based on the summary of product characteristics for each drug. Issued in May 2009.</p><p><strong>February 2009 </strong>— the supporting evidence on the risk of cardiorenal adverse effects has been updated with two new epidemiological studies that were highlighted by the MHRA as lending support to the view that some increase in thrombotic cardiovascular risk may apply to all NSAID users, irrespective of their baseline risk, but that the absolute increase in risk for 'healthy' users is very low. Issued in March 2009.</p><p><strong>February to June 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>October 2008 </strong>— minor update to text regarding prevention of gastrointestinal adverse effects. New table added, showing doses of proton pump inhibitors licensed for prophylaxis, in people with an increased risk of GI adverse effects, who require continued NSAID treatment. Issued in November 2008.</p><p><strong>January 2008 </strong>— minor update. Advice from the US Food and Drug Administration (FDA) added: the FDA advises that, when used together, the doses of ibuprofen and aspirin should be staggered to minimize any potential interaction (e.g. ibuprofen at least 30 minutes after and 8 hours before aspirin). Issued in January 2008.</p><p><strong>November 2007 </strong>— the product licence for lumiracoxib has been suspended by the MHRA (Medicines and Healthcare products Regulatory Agency) because of an increased risk of hepatotoxicity. Issued in December 2007.</p><p><strong>March 2007</strong>— updated to include advice from the Commission on Human Medicines (CHM) on the cardiovascular safety of non-selective NSAIDs. Issued in March 2007.</p><p><strong>July 2006 </strong>— updated to include advice from the Commission on Human Medicines (CHM) on NSAIDs and infertility. Issued in July 2006.</p><p><strong>October 2005 </strong>— updated to include advice from the Committee on Safety of Medicines (CSM) on the cardiovascular safety of standard NSAIDs. Issued in November 2005.</p><p><strong>July 2005 </strong>— updated to include new advice from the Committee on Safety of Medicines (CSM) and the European Medicines Agency (EMEA) on the cardiovascular safety of COX-2 selective NSAIDs. Issued in July 2005.</p><p><strong>April 2005 </strong>— updated to include new advice from the Committee on Safety of Medicines (CSM) on the safety of COX-2 selective NSAIDs. Also updated to include information published by the Medicines and Healthcare products Regulatory Agency (MHRA) about the voluntary suspension of valdecoxib. Issued in April 2005.</p><p><strong>September 2004 </strong>— written. Validated in November 2004 and issued in February 2005.</p><!-- end field 2fec161c-84b8-486c-a9d8-298412b93256 --><!-- end item 97421293-b0f4-475b-9efb-ab3a675a5b9a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}